On the track of those studies, we demonstrated the possibility of eliciting highly efficient colon cancer–specific cytotoxic T-cell lines (CTLs) by in vitro stimulating human peripheral blood mononuclear cells (PBMCs) with colon cancer cells pre-exposed to immunomodulating drugs including gemcitabine, oxaliplatin, LF, and fluorouracil (5-FU) alone or in combination (GOLF) and other chemo-immunological blends, such as granulocyte-macrophage colony stimulating factor (GM-CSF) and then low-dose human recombinant interleukin-2 (IL-2) (26, 27). This evidence concerns the gene IL2 and malignant colon neoplasm.